( OTC-PINK:RGBP, OTC-PINK:RGBPP, Bloomberg:RGBP@US, Bloomberg:RGBPP@US, RICS:RGBP, RICS:RGBPP, ISIN:US75886M1027, OTC-BB:RGBP, OTC-BB:RGBPP, OtherOTC:RGBP, OtherOTC:RGBPP )

News from Regen BioPharma, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Mar 21, 2018, 08:00 ET Regen BioPharma, Inc. Nears Completion of Optimizing its Lead NR2F6 Small Molecule Agonist

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has been methodically optimizing small molecules that bind to, and activate, the NR2F6...


Feb 21, 2018, 08:00 ET Regen BioPharma, Inc. Program to Determine the 3-D Crystal Structure of NR2F6 Progresses to Next Step

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has moved into the second stage of its previously-announced program to determine the...


Jan 17, 2018, 08:00 ET Regen BioPharma, Inc.'s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key...


Dec 11, 2017, 08:00 ET Regen BioPharma, Inc. Files Additional Composition of Matter Patent Application on NR2F6-Modulating Small Molecules

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) today announced filing a patent application covering composition of matter and methods of...


Nov 27, 2017, 18:26 ET Regen BioPharma, Inc. Begins In Vivo Assessment of Small Molecule Agonists to NR2F6 Nuclear Receptor

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has initiated in vivo and ex vivo assessments to determine the effects of some of the...


Oct 30, 2017, 08:00 ET Regen BioPharma, Inc. Announces Former Eli Lilly Executive and Current CVS Board Member will Lead Newly Formed Business Advisory Board (BAB)

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) announced that former Eli Lilly executive Jean-Pierre Millon will serve as chairman of its...


Oct 23, 2017, 08:00 ET Regen BioPharma, Inc. Begins Program to Determine the 3-Dimensional Crystal Structure of NR2F6

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has begun a program to determine the 3-dimensional structure of NR2F6 both with and without...


Oct 03, 2017, 10:00 ET Regen BioPharma, Inc. Researchers Demonstrate Direct Binding of Proprietary Agonists to Immune Checkpoint NR2F6

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) scientists have used a standard biochemical assay to determine if some of its small...


Sep 06, 2017, 08:00 ET Regen BioPharma, Inc. Researchers Identify Key Structure in Compounds that Activate NR2F6

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), in conjunction with its medicinal chemistry partner, ChemDiv, Inc., believes it has made a...


Aug 10, 2017, 07:00 ET Regen BioPharma, Inc. Addresses Potential Impact of Recent Bristol Myers Squibb's $2.3 Billion Acquisition of IFM Therapeutics

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) sees recent deal activity in the immune oncology space as an indication that big pharma...


Aug 09, 2017, 07:00 ET Regen BioPharma, Inc. Addresses Potential Impact of Recent Bristol Myers Squibb $2.3 Billion Acquisition of IFM Therapeutics

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) sees recent deal activity in the immune oncology space as an indication that big pharma...


Jul 25, 2017, 08:00 ET Regen BioPharma, Inc. Research Demonstrates Ex-Vivo Immune Suppression With Novel NR2F6 Activators

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) today reported continued progress in Regen's development of small molecule drugs that...


Jul 12, 2017, 08:00 ET Regen BioPharma, Inc. Researchers Discover New Dynamic Compound Which Modulates the NR2F6 Checkpoint

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), today reported continued progress in developing small molecule drugs that activate and...


May 16, 2017, 08:00 ET Regen BioPharma, Inc. Sees Additional Positive Results on its Medicinal Chemistry Optimization for Modulating NR2F6 Checkpoint for Treating Cancer and Autoimmune Diseases

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) states that progress continues to be achieved by Regen in developing small molecule drugs...


Apr 18, 2017, 08:00 ET Regen BioPharma, Inc. Identifies Three New Series of Compounds That Activate NR2F6

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), in conjunction with its medicinal chemistry partner, ChemDiv, Inc., has identified three...


Apr 12, 2017, 10:30 ET Regen BioPharma, Inc. Sees Success in Its Pre-Clinical Small Molecule Optimization Program for NR2F6

The Company's small molecule drug program is aimed at treating cancer and autoimmune diseases As previously reported, Regen BioPharma Inc....


Mar 23, 2017, 08:00 ET Regen BioPharma, Inc. Provides Update on NR2F6 Small Molecule Optimization Program for Treating Cancer and Arthritis

Analogues Have Been Synthesized for Lead Compounds and are Complete, now the Optimization Process is set to Begin Utilizing NR2F6 Protein...


Mar 02, 2017, 08:00 ET Regen BioPharma, Inc. Licenses NR2F6 Technology for Cancer Treatment and Autoimmune Disorders to CheckPoint Immunology Inc.

CheckPoint Formed as a Subsidiary of the Company to Simplify any Potential Future Transactions Involving the Company's NR2F6 Technology Regen...


Dec 15, 2016, 08:00 ET Regen BioPharma, Inc. Files Utility Patent Application on NR2F6-Silenced CAR-T Cell for Solid Tumors

Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) announced today the filing of a [provisional/nonprovisional] utility patent application with...


Dec 07, 2016, 08:00 ET Regen BioPharma, Inc. Discusses a Recent Important Discovery of NR2F6 in Human Cervical Cancer

Regen BioPharma Inc. (OTCQB: RGBPP) In a recent study published in the International Journal of Molecular Sciences a team of scientists in...


Nov 16, 2016, 08:00 ET Regen BioPharma's Chief Scientific Officer Harry Lander Provides Clarity on the Process of Small Molecule Development for Cancer and Autoimmune Diseases

Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) President and Chief Scientific Officer Harry Lander provides clarity for stakeholders about the...


Oct 31, 2016, 08:11 ET Regen BioPharma, Inc. Discusses Next Steps in its NR2F6 Small Molecule Program

Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) today announced its strategy for developing its novel NR2F6 small molecule modulators. Regen...


Oct 24, 2016, 08:00 ET Pan Am Cancer Treatment Center Provides Final HemaXellerate Clinical Data to Regen BioPharma, Inc. for treatment of Bone Marrow Suppression Study

Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) announced today that the Pan Am Cancer Treatment Center in Tijuana, Mexico presented final...


Sep 29, 2016, 08:00 ET Regen BioPharma, Inc. Announces the Appointment of Xiaojing Ma, PhD as the Company's New Senior Research Advisor

Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) is pleased to announce that Xiaojing Ma, Ph.D. has agreed to serve in the consulting role as...


Sep 22, 2016, 08:00 ET Regen BioPharma Responds to FDA Comments on Its Application for Orphan Drug Designation on its Aplastic Anemia Therapy

Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) has submitted additional data and other responses to the United States Food and Drug...